An Investigational Immuno-Therapy Study of Experimental Medication BMS-986277 Given Alone and in Combination With Nivolumab in Epithelial Cancers



Status:Recruiting
Conditions:Cancer, Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:4/4/2019
Start Date:November 24, 2017
End Date:December 29, 2022
Contact:Recruiting sites have contact information. Please contact the sites directly. If there is no contact information,
Email:Clinical.Trials@bms.com
Phone:please email:

Use our guide to learn which trials are right for you!

Phase 1/2a First in Human Study of BMS-986277 Administered Alone and in Combination With Nivolumab in Advanced Epithelial Tumors

The purpose of this study is to investigate experimental medication BMS-986277 given alone
and in combination with Nivolumab in patients with epithelial cancers.


For more information regarding Bristol-Myers Squibb Clinical Trial participation, please
visit www.BMSStudyConnect.com

Inclusion Criteria:

- Histological or cytological confirmation of metastatic and/or unresectable metastatic
colorectal, prostate, pancreatic, breast, ovarian, or urothelial carcinoma with
measureable disease for solid tumors per RECIST v1.1 and for prostate carcinoma per
PCWG3

- Presence of at least 2 lesions: at least one with measurable disease as defined by
RECIST v1.1 for solid tumors and by PCWG3 for prostate carcinoma for response
assessment; at least 1 lesion must be accessible for biopsy in addition to the target
lesion

- Participants must have received, and then progressed or been intolerant to, at least 1
standard treatment regimen in the advanced or metastatic setting, if such a therapy
exists, and have been considered for all other potentially efficacious therapies prior
to enrollment

- ECOG performance status less than or equal to 2

Exclusion Criteria:

- Participants with active central nervous system (CNS) metastases, untreated CNS
metastases, or with the CNS as the only site of disease

- Participants with carcinomatous meningitis

- Cytotoxic agents, unless at least 4 weeks have elapsed from last dose of prior
anti-cancer therapy and initiation of study treatment

- Participants with active, known, or suspected autoimmune disease

Other protocol defined inclusion/exclusion criteria could apply
We found this trial at
6
sites
Boston, Massachusetts 02111
?
mi
from
Boston, MA
Click here to add this to my saved trials
Camperdown, New South Wales 2050
?
mi
from
Camperdown,
Click here to add this to my saved trials
La Jolla, California 92093
?
mi
from
La Jolla, CA
Click here to add this to my saved trials
New York, New York 10016
?
mi
from
New York, NY
Click here to add this to my saved trials
Phoenix, Arizona 85016
?
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Sioux Falls, South Dakota 65104
Phone: 605-328-1361
?
mi
from
Sioux Falls, SD
Click here to add this to my saved trials